Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction
Autor: | Xiaoli Wang, Wenguo Xu, Yuansheng Hu, Hui Yao, Li Xu, Minhua Ma, Ying Zhang, Yalong Wang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023) |
Druh dokumentu: | article |
ISSN: | 2164-5515 2164-554X 21645515 |
DOI: | 10.1080/21645515.2023.2227549 |
Popis: | Healive® was the only Chinese WHO-prequalified inactivated vaccine for the hepatitis A virus, which has been widely used in national immunization programs in China. Long-term follow-up studies are needed to estimate the persistence of vaccine-induced antibody levels and the necessity for booster vaccines. During the trial, geometric mean concentrations (GMCs) and seroconversion rates (SRs) of anti-HAV antibodies were compared based on two different inactivated hepatitis A vaccines, Healive® and Havrix®. Four hundred children were randomly assigned to receive two doses of Healive® or Havrix® at 0 and 6 months. The current study assessed antibody persistence for both vaccines 15 years post-immunization. A mixed linear model was used to predict long-term antibody persistence. The GMCs were significantly higher for Healive® compared to Havrix® at 1, 6, 7, 66, 138 months (P |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |